REDWOOD CITY, Calif. , Nov. 15, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on November 7, 2024 , the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 37,726 shares of Nevro's common stock to 24 new non-executive... Read More

HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark evidence with cloud data insights, leading the way for personalized, data-driven patient care* REDWOOD CITY, Calif. , Nov. 12, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is... Read More

Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif. , Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year... Read More

Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic Neuropathy and Type 2 Diabetes REDWOOD CITY, Calif. , Oct. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic... Read More

REDWOOD CITY, Calif. , Oct. 16, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on October 7, 2024 , the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 26,088 shares of Nevro's common stock to five new non-executive... Read More

REDWOOD CITY, Calif. , Oct. 10, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the third quarter of 2024 after the market closes on Monday, November 11, 2024 . The company will also host a conference call beginning at 1:30 p.m. PST ( 4:30 p.m. EST... Read More

HFX AdaptivAI combines insights from over 100,000 patients and more than 100 million data points¹ and leverages artificial intelligence (AI) to deliver responsive and personalized pain relief in real time* REDWOOD CITY, Calif. , Sept. 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is... Read More

REDWOOD CITY, Calif. , Sept. 19, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on September 7, 2024 , the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 51,543 shares of Nevro's common stock to 21 new non-executive... Read More

REDWOOD CITY, Calif. , Aug. 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in a "fireside chat" (question-and-answer) session at the Wells Fargo 2024 Healthcare Conference on Friday, September 6, 2024 , beginning at 8:45 a.m. EDT... Read More

REDWOOD CITY, Calif. , Aug. 14 , 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on August 7, 2024 , the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 10,199 shares of Nevro's common stock to four new non-executive... Read More

Initiates Process Aimed at Accelerating Growth, Diversifying Product Portfolio and Maximizing Stockholder Value Revises Full-Year 2024 Revenue Guidance to a Range of $400 million to $405 million and Adjusted EBITDA Guidance to a Range of $(20) Million to $(18) Million Provides Third-Quarter 2024 Guidance REDWOOD CITY, Calif. , Aug. 6, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is... Read More

REDWOOD CITY, Calif. , July 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on July 7, 2024 , the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 69,201 shares of Nevro's common stock to 17 new non-executive employees... Read More

REDWOOD CITY, Calif. , July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the second quarter of 2024 after the market closes on Tuesday, August 6, 2024 . The company will also host a conference call beginning at 1:30 p.m. PDT ( 4:30 p.m. EDT )... Read More

REDWOOD CITY, Calif. , June 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on June 7, 2024 , the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 56,692 shares of Nevro's common stock to 17 new non-executive employees... Read More

REDWOOD CITY, Calif. , June 11 , 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in a "fireside chat" (question-and-answer) session at the Truist Securities MedTech Conference on Tuesday, June 18, 2024 , beginning at approximately 8:40... Read More

REDWOOD CITY, Calif. , May 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on May 7, 2024 , the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 59,460 shares of Nevro's common stock to twenty-six new non-executive... Read More

REDWOOD CITY, Calif. , May 9, 2024 /PRNewswire/ -- Nevro Corp . (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in the BofA Securities 2024 Healthcare Conference on Tuesday, May 14, 2024 . The company's formal presentation will begin at 9:20 am PDT ( 12:20 am EDT ). A... Read More

Announces Additional Restructuring Steps to Advance Strategy and Accelerate Profitability Raises Adjusted EBITDA Guidance and Reaffirms Revenue Guidance for Full-Year 2024 Promotes Christofer Christoforou to Chief Operating Officer REDWOOD CITY, Calif. , May 7, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic... Read More

REDWOOD CITY, Calif. , April 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the first quarter of 2024 after the market closes on Tuesday, May 7, 2024 . The company will also host a conference call beginning at 1:30 p.m. PDT ( 4:30 p.m. EDT ) to... Read More

Nevro1™ Proven to Immediately Transfix Sacroiliac (SI) Joint to Allow for Long-term SI Joint Fusion REDWOOD CITY, Calif. , Feb. 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the U.S. Food and Drug Administration (FDA) cleared its sacroiliac joint fusion device, which will be marketed... Read More

Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif. , Feb. 21, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has entered into a Cooperation Agreement with Engaged... Read More

Provides Full-Year and First-Quarter 2024 Guidance REDWOOD CITY, Calif. , Feb. 21, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2023 financial results. The company also provided first-quarter and full-year 2024 financial guidance. "Our fourth quarter... Read More

Experts in diabetes, pain and health services from the Worldwide Initiative for Diabetes Education recommend spinal cord stimulation when symptoms aren't responsive to first- or second-line therapies REDWOOD CITY, Calif. , Feb. 1, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the... Read More

REDWOOD CITY, Calif. , Jan. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 after the market closes on Wednesday, February 21, 2024 . The company will also host a... Read More

Spinal Cord Stimulation Coverage Policy to Include 43 Million Additional Covered Lives REDWOOD CITY, Calif. , Jan. 18, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Carelon Healthcare , a healthcare services company dedicated to delivering whole-person care with connected... Read More

Presentations review clinical results of 10 kHz Therapy™ for the treatment of chronic back and leg pain, non-surgical back pain (NSBP), and painful diabetic neuropathy (PDN) REDWOOD CITY, Calif. , Jan. 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced a series of data presentations supporting... Read More

Fourth-Quarter 2023 Worldwide Revenue Exceeds Company's Expectations Announces Restructuring to Support Company's Long-Term Growth and Profitability REDWOOD CITY, Calif. , Jan. 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its preliminary, unaudited fourth-quarter and full-year 2023... Read More

REDWOOD CITY, Calif. , Jan. 4, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 . The company's formal presentation will begin at 8:15 am PST ( 11:15 am... Read More

Refinances with $200M Structured Debt Maturing in 2029 REDWOOD CITY, Calif. , Nov. 30, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has acquired Vyrsa Technologies ("Vyrsa"), a privately held medical technology company focused on a minimally invasive treatment option for... Read More

Data Published in Journal of Neurosurgery: Spine Highlight Lasting Pain Relief, Enhanced Function, Quality of Life, and Reduced Opioid Dependency with High-Frequency SCS Therapy REDWOOD CITY, Calif. , Nov. 20, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new... Read More

REDWOOD CITY, Calif. , Nov. 1, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third quarter 2023 financial results. The Company also provided fourth quarter guidance and updated its full-year 2023 guidance. Recent Business Highlights and Guidance Third Quarter 2023 Worldwide Revenue... Read More

Company to Host Conference Call on Wednesday, November 1, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif. , Oct. 4, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company... Read More

Publications Show Reductions in Hospital Resource Utilization Associated with 10 kHz Therapy Spinal Cord Stimulation for the Treatment of Painful Diabetic Neuropathy and Nonsurgical Refractory Back Pain REDWOOD CITY, Calif. , Sept. 18, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the... Read More

REDWOOD CITY, Calif. , Aug. 23, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced today that it is participating in the following investor conferences: On September 7, 2023 , Kevin Thornal , Chief Executive Officer and President, and Rod MacLeod , Chief Financial Officer will present at the Wells Fargo... Read More

Evidence Published in Diabetes Research and Clinical Practice Shows 10 kHz Therapy Yields Lasting Pain Relief and Enhances Health-Related Quality of Life and Sleep REDWOOD CITY, Calif. , Aug. 16, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of 24-month data from the SENZA... Read More

Company Takes Proactive Steps to Improve Commercial Execution and Maximize Growth Opportunities REDWOOD CITY, Calif. , Aug. 1, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its second quarter 2023 financial results. The company also provided third quarter guidance and updated its... Read More

Abstract Presentations Highlight Durable Pain Relief and Improved Quality of Life for Patients Receiving 10 kHz Spinal Cord Stimulation Therapy for Painful Diabetic Neuropathy and Non-Surgical Back Pain Symposium on the Future of SCS and How AI Technology Can Improve Outcomes with HFX iQ™ REDWOOD CITY, Calif. , July 13, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering... Read More

Wednesday, August 9, 2023 at 8:30 am Eastern Time REDWOOD CITY, Calif. , July 12, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Kevin Thornal , Nevro's CEO and President, and Rod MacLeod , Nevro's CFO, will present at the Canaccord Genuity 43 rd Annual Growth Conference on... Read More

Company to Host Conference Call on Tuesday, August 1, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif. , June 27, 2023 /PRNewswire/ -- Nevro Corp . (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the second quarter ended June 30, 2023 after the market closes on... Read More

Presentation to Discuss Correlation Between Use of High-Frequency (10 kHz) Spinal Cord Stimulation and Reductions in HbA1c and Body Weight Nevro to Participate in ADA's Painful Diabetic Neuropathy Symposium and Host Product Theater Presentation REDWOOD CITY, Calif. , June 23 , 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the... Read More

Organizational Change Designed to Drive Strong Growth and Advance Global Commercial Focus Company Updates Second Quarter 2023 Revenue Guidance REDWOOD CITY, Calif. , June 5, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Greg Siller has been appointed Senior Vice President and... Read More

Thursday, June 8, 2023 at 10:30 am Eastern Time REDWOOD CITY, Calif. , May 22, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Kevin Thornal , Nevro's CEO and President, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 10:30 am Eastern Time at the... Read More

REDWOOD CITY, Calif. , April 27, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced on April 24, 2023 , the Board of Director of Nevro granted restricted stock unit awards covering an aggregate of 135,623 shares of its common stock (the RSU Award) and performance unit awards covering... Read More

REDWOOD CITY, Calif. , April 26, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its first quarter 2023 financial results. The company also provided second quarter guidance and reiterated its full-year 2023 guidance. Recent Business Highlights and Guidance First Quarter 2023 Worldwide... Read More

First Randomized Controlled Trial Specifically Powered to Assess Restoration of Neurological Function in Patients with Intractable Painful Diabetic Neuropathy Breakthrough Device Designation Provides Expedited Review for Marketing Application to Expand Nevro's FDA Labeling REDWOOD CITY, Calif. , April 24, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive,... Read More

REDWOOD CITY, Calif. , April 24, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced today that it is participating in the following investor conferences: On May 10, 2023 , Kevin Thornal , CEO & President, and Rod MacLeod , Chief Financial Officer, will present at the Bank of America 2023 Health... Read More

D. Keith Grossman to be Appointed as Executive Chairman Company Announces Preliminary, Unaudited Worldwide Revenue for First Quarter of 2023 of $96.3 Million and Reaffirms Full-Year 2023 Revenue and Non-GAAP Adjusted EBITDA Guidance REDWOOD CITY, Calif. , April 19, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global... Read More

Company to Host Conference Call on Wednesday, April 26, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif. , March 29, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company... Read More

Senza® HFX iQ™ is the First and Only SCS System that Uses Artificial Intelligence to Optimize and Maintain Pain Relief Using Each Patient's Response REDWOOD CITY, Calif. , March 7, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the... Read More

Company to Host Conference Call on Thursday, February 16, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif. , Jan. 19, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the fourth quarter and full year ended December 31, 2022 after... Read More

REDWOOD CITY, Calif. , Jan. 12, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the company's HFX™ 10 kHz Therapy for patients with chronic pain. Results will be presented at the 2023 North American Neuromodulation Society (NANS) Annual... Read More

Company Announces 2023 Retirement Plans of D. Keith Grossman from Positions of CEO and President; Will Remain as Chairman of the Board Company to Present Today at J.P. Morgan Healthcare Conference at 3:45 pm Pacific Time REDWOOD CITY, Calif. , Jan. 9, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,... Read More

Monday, January 9, 2023 at 3:45 pm Pacific Time / 6:45 pm Eastern Time REDWOOD CITY, Calif. , Dec. 19, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman , Nevro's Chairman, CEO and President, will present at the 41 st Annual J.P. Morgan Healthcare Conference on Monday,... Read More

SENZA-PDN 24-Month Follow-Up Results to be Presented on January 14, 2023 SENZA-NSRBP 24-Month Follow-Up Results to be Presented on January 13, 2023 REDWOOD CITY, Calif. , Dec. 14, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that two abstracts for Painful Diabetic Neuropathy (PDN) and... Read More